Augplat 250 mcg Injection for Chronic ITP – Product Details and Uses

Augplat 250 mcg Injection (Romiplostim) is a prescription medicine used to manage low platelet counts associated with chronic immune thrombocytopenia (ITP) in eligible patients. Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical product information and handles enquiries for international supply, subject to applicable export and destination-country regulatory requirements.

Product Description: Augplat 250 mcg Injection

Augplat 250 mcg Injection contains romiplostim, a thrombopoietin receptor agonist that stimulates platelet production in the bone marrow. It may be prescribed for patients with chronic ITP who have not responded adequately to certain previous treatments, such as corticosteroids or immunoglobulins.

ITP is an immune-related condition in which platelets are destroyed by the immune system, potentially increasing the risk of bruising and bleeding. Romiplostim helps increase platelet counts to reduce the risk of clinically significant bleeding.

Product details:

Brand name: Augplat

Strength: 250 mcg

Active ingredient: Romiplostim

Dosage form: Injection

Therapeutic category: Thrombopoietin receptor agonist

Primary use: Management of chronic immune thrombocytopenia (ITP) in eligible patients

Administration: Subcutaneous injection under qualified medical supervision

Product composition, approved indications, packaging and storage requirements should be confirmed against the product-specific prescribing information.

Benefits and Uses of Augplat 250 mcg Injection

Augplat 250 mcg Injection may offer the following therapeutic benefits when prescribed appropriately:

1. Supports platelet production: Romiplostim stimulates the bone marrow to produce more platelets, helping address low platelet counts associated with ITP.

2. Helps reduce bleeding risk: Maintaining an appropriate platelet count may help reduce the risk of clinically significant bleeding in eligible patients.

3. An option after previous treatment: It may be considered when certain established ITP treatments have not provided an adequate response.

4. Supports ongoing disease management: Regular platelet monitoring allows healthcare professionals to assess treatment response and adjust therapy when necessary.

Treatment goals are individualized. The medicine is not intended to normalize platelet counts or cure ITP.

Side Effects and Safety Information

Like other prescription medicines, Augplat may cause side effects. Reported adverse effects associated with romiplostim include:

Headache and dizziness

Joint pain and muscle pain

Pain in the arms, legs or shoulders

Abdominal discomfort, nausea or indigestion

Tingling or numbness

Sleep disturbances

Important safety warning: Romiplostim can increase the risk of blood clots, including potentially serious thromboembolic complications. Unusual bleeding, severe headache, chest pain, sudden breathlessness or one-sided leg swelling requires urgent medical assessment.

Platelet counts must be monitored regularly during treatment and after discontinuation. Do not start, stop or change the dose without consulting the treating specialist.

Frequently Asked Questions (FAQs)

1. What is Augplat 250 mcg Injection used for?

It is used to manage low platelet counts associated with chronic immune thrombocytopenia in eligible patients, according to the approved product information.

2. What is the active ingredient in Augplat Injection?

The active ingredient is romiplostim, which stimulates platelet production in the bone marrow.

3. How is Augplat 250 mcg Injection administered?

Romiplostim is administered as a subcutaneous injection by a qualified healthcare professional. The prescribed dose and frequency depend on the patient's weight, platelet response and clinical condition.

4. Does Augplat have side effects?

Yes. Headache, joint pain, dizziness and muscle pain may occur. Blood clots and other serious complications are also possible.

5. How can international buyers enquire about Augplat 250 mcg Injection?

Hospitals, licensed pharmaceutical distributors and eligible importers can contact Cordium Pharmaceuticals Pvt Ltd to enquire about product availability, quotation, packaging and export documentation. Supply is subject to prescription-drug regulations and import authorization in the destination market.

International Pharmaceutical Supply Enquiries

Cordium Pharmaceuticals Pvt Ltd welcomes legitimate enquiries from hospitals, licensed distributors and authorized pharmaceutical importers seeking information about Augplat 250 mcg Injection. Buyers may request a quotation, product specifications, available packaging details and applicable export documentation.

All orders are subject to product availability, verification of buyer credentials and compliance with applicable pharmaceutical export and import regulations.

Medical disclaimer: This content is for general informational purposes and does not replace professional medical advice or the approved product leaflet.